Literature DB >> 6896785

Early remission in thyrotoxicosis produced by short courses of treatment.

R F Bing, F D Rosenthal.   

Abstract

Twenty-eight patients with Graves' disease were treated with short-term antithyroid drug therapy. i.e. treatment was discontinued as soon as they became euthyroid. This was less than 4 months in all patients. Ten patients remained euthyroid, although in two of these, thyrotoxicosis recurred after the patients had been euthyroid for more than 2 months. The other 18 patients relapsed within 12 weeks of stopping therapy, and only two have become euthyroid after a further 12 month period of treatment. All patients who remitted were thyrotoxic for the first time whereas all patients with a past history of thyroid disease relapsed. Positive thyroid microsomal antibody titres were more frequent in patients who remitted, otherwise there were no indicators of a favourable outcome. The remission rate with antithyroid therapy which is only continued until the patient becomes euthyroid is similar to that for treatment lasting 12--18 months. Short-term therapy has the advantage of savings in both patient and clinician time.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6896785     DOI: 10.1530/acta.0.1000221

Source DB:  PubMed          Journal:  Acta Endocrinol (Copenh)        ISSN: 0001-5598


  4 in total

1.  Management of patients with diffuse toxic goitre in Ireland, a country with low iodine intake.

Authors:  A Smith; T J McKenna
Journal:  Ir J Med Sci       Date:  1992-10       Impact factor: 1.568

2.  Optimum duration of antithyroid drug treatment determined by assay of thyroid stimulating antibody in patients with Graves' disease.

Authors:  G Edan; C Massart; B Hody; J Y Poirier; M Lé Reun; J P Hespel; G Leclech; M Simon
Journal:  BMJ       Date:  1989-02-11

3.  Antithyroid drug and Graves' hyperthyroidism. Significance of treatment duration and TRAb determination on lasting remission.

Authors:  R V García-Mayor; C Páramo; R Luna Cano; L F Pérez Mendez; J C Galofré; A Andrade
Journal:  J Endocrinol Invest       Date:  1992-12       Impact factor: 4.256

Review 4.  Pediatric Graves' disease: management in the post-propylthiouracil Era.

Authors:  Scott A Rivkees
Journal:  Int J Pediatr Endocrinol       Date:  2014-06-16
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.